Loading...
Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review
Amyloid-beta (Aβ) in Alzheimer's disease (AD) appeared to be a promising target for disease-modifying therapeutic strategies like passive immunotherapy with anti-Aβ monoclonal antibodies (mAbs). Biochemical markers in cerebrospinal fluid (CSF) include alterations of Aβ that allow the diagnosis...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3698450/ https://ncbi.nlm.nih.gov/pubmed/23847530 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fnagi.2013.00025 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|